Allena Pharmaceuticals, Inc. ALNA Income Statement

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Sep'16
Operating expenses:
Research and development
32,762	37,244	35,792	32,302	29,573	26,376	23,868	19,501	17,099	15,519	16,021	0	0	0
General and administrative
10,123	9,676	10,220	10,077	9,606	9,217	8,516	7,540	6,282	5,431	4,460	0	0	0
Total operating expenses
43,490	47,525	46,012	42,379	39,179	35,593	30,175	24,945	0	-	0	0	-	-
Total operating expenses
-	-	-	-	-	-	-	-	-	-	-	-	0	0
Loss from operations
0	-	0	0	0	-	0	0	0	-	0	0	0	0
Other income (expense):
Interest income (expense), net
65	270	459	586	626	575	356	30	-211	-443	-443	0	0	0
Other expense, net
-	-	-	0	-	-	-	0	0	-	-	-	-	-
Other expense, net
0	-	0	-	0	-	0	-	-	-257	-185	0	0	0
Loss on extinguishment of debt
-	-	-	-	-	-	-	0	-	-	-	-	-	-
Other income (expense), net
-15	186	421	566	-8	-55	-330	-833	-478	-700	-628	0	0	0
Net loss
-43,505	-47,339	-45,591	-41,813	-39,187	-35,648	-32,714	-27,874	-23,859	-21,650	-21,109	0	0	0
Net loss per share attributable to common stockholders—basic and diluted
-0.31	-0.47	-0.57	-0.54	-0.55	-0.46	-0.46	-0.42	-0.38	6.39	-3.49	-3.46	-4.24	-4.59
Weighted-average common shares outstanding—basic and diluted
24,737	23,540	23,464	20,903	20,814	20,783	20,753	20,733	20,695	14,052	1,343	1,342	1,342	1,341
Net loss
-43,505	-47,339	-45,591	-41,813	-39,187	-35,648	-32,714	-27,874	-23,859	-21,650	-21,109	0	0	0
Unrealized loss on investments
-	-	-	-	-	-	-	-	-	-	0	0	0	-
Total other comprehensive loss
-	-	-	-	-	-	-	-	-	-	0	0	0	-
Comprehensive loss
-43,505	-47,339	-45,591	-41,813	-39,187	-35,648	-32,716	-27,876	-23,858	-21,650	-21,107	0	0	0